NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc
NEW YORK, Nov.
REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc.
New York, NY and Santa Barbara, CA The American Federation for Aging Research (AFAR) and the Glenn Foundation for Medical Research announce the 2021 recipients of three grant programs:the Glenn Foundation for Medical Research and AFARGrants for Junior Faculty, the Glenn Foundation for Medical ResearchPostdoctoral Fellowships in Aging Research,andthe Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Awards.Collectively, these three grant programs will provide close to $2,260,000 in support of biomedical research on aging. TheBreakthroughs in Gerontology (BIG) Awardsprovide $300,000 for research projects that offer significant promise of yielding transforming discoveries in the fundamental biology of aging or that build on early discoveries with the potential for translation to clinically relevant strategies, treatments, and therapeutics to benefit human aging and healthspan. TheGrants for Junior Facultyprovide early career investigators with up to $100,000 to support research focused on biological aging processes.
Clearly, stem cells are not a cure-all: but what can science do to bring them closer to this ideal?
REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov.
The research analysis report on the Global Stem Cell Characterization and Analysis Tool Market examines historical data and emerging technologies to identify the key drivers influencing the development of the industry. The report also contains expert advice that helps consumers focus on their development goals and make informed decisions
Worldwide Stem Cell Umbilical Cord Blood (UCB) Market report s a professional and detailed report focusing on, key players, major collaborations, mergers & acquisitions over the forecast period. Further, this report showcases the trending innovation and current upgrades happening to this industry.
Lead program, CNTY-101 in relapsed/refractory non-Hodgkins lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iTplatform to be presented at the ASH Annual Meeting Research and development update to be held on Thursday, December 16, 8:00-9:30 AM EST Made significant investment in building in-house manufacturing facility and new laboratory space Ended third quarter with cash, cash equivalents, and marketable securities of $400.3M PHILADELPHIA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2021. We continue to deepen investments in cellular reprogramming, genetic engineering, and manufacturing, in order to advance our iPSC platforms, with an ultimate goal of developing therapies that can meaningfully advance cancer care, said Lalo Flores, Chief Executive Officer, Century Therapeutics.
Conference showcased the impact funds raised at the annual networking event over the past 10 years have had on helping Boston Childrens Hospital find answers about childhood disease BOSTON --News Direct-- Boston Childrens Hospital Last week Boston Childrens Hospital gathered together the brightest minds in the financial investment community for a full day of sharing insights, ideas and networking opportunities at its annual Boston Investment Conference. Since its launch in 2011, the Boston Investment Conference (BIC) has raised funds to help fuel the development of life-changing innovations for the worlds sickest children. Cumulatively the event has raised over $20 million since its founding to drive transformative research at Boston Childrens and strengthen scientific collaborations with the Broad Institute of MIT and Harvard
Recent Comments